IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
MWN-AI** Summary
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced a conference call scheduled for March 31, 2026, at 11:00 a.m. EDT. The call aims to discuss the company’s financial performance for the year ended December 31, 2025, alongside updates on its clinical development program, focusing on its lead candidate, IMNN-001, a DNA-based immunotherapy targeting advanced ovarian cancer.
IMNN-001 utilizes DNA-mediated technology to produce significant levels of interleukin-12 (IL-12) at tumor sites, fostering an effective immunological response. This approach distinguishes IMUNON’s therapies from conventional treatment methods. The company is currently in Phase 3 of its clinical trials (OVATION 3) following the completion of a Phase 2 trial (OVATION 2). Additionally, IMUNON has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Investors and interested parties can participate in the call by dialing 800-715-9871 or 646-307-1963, or by accessing a live webcast. An audio replay of the call will be available for 90 days post-event.
IMUNON focuses on advancing its non-viral DNA technology, with applications in various disease treatments, including solid tumors and infectious diseases. Its modalities include TheraPlas®, for the gene-based delivery of therapeutic proteins, and PlaCCine®, for the gene delivery of viral antigens. The company aims to enhance patient outcomes in challenging medical scenarios, leveraging partnerships to expand its reach in the biotechnology market.
Forward-looking statements within the announcement indicate that potential risks and uncertainties may impact IMUNON’s plans and the efficacy of its therapies, as recognized in accordance with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. For more information, visit IMUNON's website.
MWN-AI** Analysis
As IMUNON, Inc. prepares for its Year-End 2025 Financial Results and Business Update Conference Call on March 31, 2026, investors are advised to adopt a “Hold” position on their shares. This recommendation stems from several key factors surrounding the company’s current operational status and future prospects.
IMUNON is deeply engaged in the clinical development of its lead candidate, IMNN-001, a promising DNA-based immunotherapy for advanced ovarian cancer. The transition to Phase 3 in the OVATION 3 trial signifies a crucial phase in its development; however, outcomes from these trials can represent a significant risk due to market volatility and the uncertainties inherent in clinical results. Moreover, with the company having completed a Phase 2 trial, the market will be acutely interested in the data expected to be released during the call pertaining to these pivotal studies.
Additionally, IMUNON's dual focus on the TheraPlas® and PlaCCine® platforms shows promise, especially in niche therapy segments, though potential competitive pressures and regulatory hurdles remain. The upcoming discussion on financial results will be critical, providing insight into the company's funding status, cash burn rate, and how well-positioned it is for upcoming trials.
Given the volatile landscape of biotech stocks, particularly concerning clinical-stage companies, a Hold rating allows investors to observe upcoming results from the call without prematurely committing capital amidst the uncertainty. Investors should focus on management's guidance regarding timelines, expected outcomes, strategic partnerships, and how the latest data aligns with market expectations.
In summary, while IMUNON exhibits strong potential within its therapeutic areas, the upcoming conference call may illuminate both challenges and opportunities; strategic patience is advised as more information unfolds.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.
The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available here.
An audio replay of the call will be available for 90 days and can be accessed at 800-770-2030 (U.S. and Canada/Toll Free), 609-800-9909 (U.S./Toll) or 647-362-9199 (Canada/Toll) using replay access code 4157104#.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ**
What key financial metrics will IMUNON Inc. (IMNN) discuss during the conference call on March 32026, regarding its performance for the year ended December 32025?
Can IMUNON Inc. (IMNN) provide insights into the progress and expected milestones for the Phase 3 clinical trial of IMNN-001 during the upcoming conference call?
How does IMUNON Inc. (IMNN) plan to leverage its TheraPlas® and PlaCCine® modalities in the future, and what updates can we expect on these technologies during the call?
What are the anticipated timelines and potential challenges discussed by IMUNON Inc. (IMNN) concerning the development of its COVID-19 booster vaccine, IMNN-101, in the forthcoming investor call?
**MWN-AI FAQ is based on asking OpenAI questions about Imunon Inc. (NASDAQ: IMNN).
NASDAQ: IMNN
IMNN Trading
-5.29% G/L:
$2.80 Last:
47,242 Volume:
$2.80 Open:
